Corvus Pharma Q4 EPS $(0.14) Misses $(0.12) Estimate
Portfolio Pulse from Happy Mohamed
Corvus Pharma (NASDAQ:CRVS) reported Q4 earnings with losses of $(0.14) per share, missing the consensus estimate of $(0.12) by 16.67%. However, this represents a 33.33% improvement over the previous year's losses of $(0.21) per share.
March 19, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Corvus Pharma reported Q4 losses of $(0.14) per share, missing estimates but showing year-over-year improvement.
Missing the consensus estimate typically has a negative short-term impact on a company's stock price. However, the year-over-year improvement in losses might mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100